ISOGINKGETIN

Research use only, not for human use.

Isoginkgetin, a compound derived from the leaves of Ginkgo biloba, to up-regulate adiponectin secretion with potency comparable to that of rosiglitazone, a known modulator of adiponectin production.

Isoginkgetin, a compound derived from the leaves of Ginkgo biloba, to up-regulate adiponectin secretion with potency comparable to that of rosiglitazone, a known modulator of adiponectin production. Isoginkgetin has anti-tumor activity, the mechanistic basis is splicing inhibition , thus, pre-mRNA splicing inhibitors may represent a novel avenue for development of new anti-cancer agents.Isoginkgetin can inhibit tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. Isoginkgetin (0.3mg/kg ip for 3d) can reduce the level of O2·- in plasma and erythroeyte and sometimes increase the activity of SOD in anoxic rats, the action being stronger than aspirin.

Isoginkgetin (0-20 μM, 24 h) inhibits cell invasion in a dose-dependent manner.Isoginkgetin (10 μM, 0-24 h) induces the accumulation of ubiquitinated protein cargo into perinuclear aggregates, activates autophagy and induces lysosomal swelling, repositioning, and acidification.Isoginkgetin (10 μM, 0-6 h) induces ER stress, impairs the unfolded protein response, and results in accumulation of ERAD substrates.Isoginkgetin directly inhibits the chymotrypsin-, trypsin-, and caspase-like activities of the 20S proteasome and impairs NF-κB signaling.Isoginkgetin (30 μM, 0-24 h) induces apoptosis in MM cell lines. Cell Invasion Assay Cell Line:MDA-MB-231 and B16F10 Concentration:0, 5, 10 and 20 μM Incubation Time:24 h Result:Inhibited cell invasion in a dose-dependent manner.Western Blot AnalysisCell Line:HeLa cells and MM cell lines (MM1S, 8826, OPM2, H929, JJN3 and U266)Concentration:10?μM in HeLa cells, 30 μM in MM cell linesIncubation Time:0-24 hResult:Induced the expression of cleaved PARP-1 and Casp-3. Increased the protein levels of both ATF4 and ATF3. Decreased the level of LC3 I. Increased TFEB activation. Prevented the degradation of IκBα in response to stimulation with TNF-α.Cell Viability Assay Cell Line:MM1S, 8826, OPM2, H929, JJN3 and U266 cells Concentration:Incubation Time:72?h Result:Inhibited cell viability with IC50 values of 3.992, 3.716, 4.749, 2.564, 3.806 and 4.147 μM against MM1S, 8826, OPM2, H929, JJN3 and U266 cells, respectively.

Isoginkgetin (4 mg/kg; i.p.; daily for 14 days) shows anti-inflammatory effects. Animal Model:Adult male Kunming mice (age 8–10weeks, 30–50 g)Dosage:4 mg/kg Administration:Daily for 14 days by intraperitoneally (i.p.) prior to LPS (0.83mg/kg) administration.Result:Markedly suppressed the production of IL-1β, IL-6, tumor necrosis factor-alpha, cyclooxygenase-2, inducible nitric oxide, and reactive oxygen species.

Isoginkgetin | IGG

Others

Other Targets

Others

Cancer

——

548-19-6

566.51

C32H22O10

>98% (HPLC)

DMSO : ≥ 83.3 mg/mL; 147.04 mM

COC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4=C(C=CC(=C4)C5=CC(=O)C6=C(C=C(C=C6O5)O)O)OC

8-[5-(5,7-Dihydroxy-4-oxochromen-2-yl)-2-methoxyphenyl]-5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one

(-20℃)

With Ice Pack

≥ 2 years